High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells

Cell Reports

Volumn 15, Issue 9, 2016, Pages 1986-1999

  Ingale, Jidnyasa ^a   Stano, Armando ^a   Guenaga, Javier ^a   Sharma, Shailendra Kumar ^a   Nemazee, David ^a   Zwick, Michael B ^a   Wyatt, Richard T ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOSOME; NANOPARTICLE; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING KINETICS; CONTROLLED STUDY; ELECTRON MICROSCOPY; EX VIVO STUDY; GERMINAL CENTER; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICULATE MATTER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; CHEMISTRY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTERFEROMETRY; LEPORIDAE; LYMPHOCYTE ACTIVATION; METABOLISM; PROTEIN MULTIMERIZATION; SOLUBILITY; TEMPERATURE; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV-1; INTERFEROMETRY; LIPOSOMES; LYMPHOCYTE ACTIVATION; MICE, INBRED C57BL; NANOPARTICLES; PROTEIN MULTIMERIZATION; RABBITS; SOLUBILITY; TEMPERATURE;

EID: 84971254705     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.04.078     Document Type: Article

References (38)

1. Arsov Z., Quaroni L. Direct interaction between cholesterol and phosphatidylcholines in hydrated membranes revealed by ATR-FTIR spectroscopy. Chem. Phys. Lipids 2007, 150:35-48.
2. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007, 360:329-340.
3. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
4. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
5. Caldeira Jdo.C., Medford A., Kines R.C., Lino C.A., Schiller J.T., Chackerian B., Peabody D.S. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010, 28:4384-4393.
6. Canfield S., Lee Y., Schröder A., Rothman P. Cutting edge: IL-4 induces suppressor of cytokine signaling-3 expression in B cells by a mechanism dependent on activation of p38 MAPK. J. Immunol. 2005, 174:2494-2498.
7. Deml L., Kratochwil G., Osterrieder N., Knüchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997, 235:10-25.
8. Falkowska E., Le K.M., Ramos A., Doores K.J., Lee J.H., Blattner C., Ramirez A., Derking R., van Gils M.J., Liang C.H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
9. Grundner C., Mirzabekov T., Sodroski J., Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 2002, 76:3511-3521.
10. Guenaga J., de Val N., Tran K., Feng Y., Satchwell K., Ward A.B., Wyatt R.T. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog. 2015, 11:e1004570.
11. Hu J.K., Crampton J.C., Cupo A., Ketas T., van Gils M.J., Sliepen K., de Taeye S.W., Sok D., Ozorowski G., Deresa I., et al. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J. Virol. 2015, 89:10383-10398.
12. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
13. Kamala T. Hock immunization: a humane alternative to mouse footpad injections. J. Immunol. Methods 2007, 328:204-214.
14. Kovacs J.M., Noeldeke E., Ha H.J., Peng H., Rits-Volloch S., Harrison S.C., Chen B. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc. Natl. Acad. Sci. USA 2014, 111:18542-18547.
15. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
16. Li Y., O'Dell S., Wilson R., Wu X., Schmidt S.D., Hogerkorp C.M., Louder M.K., Longo N.S., Poulsen C., Guenaga J., et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J. Virol. 2012, 86:11231-11241.
17. Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476. NISC Comparative Sequencing Program.
18. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
19. Ota T., Doyle-Cooper C., Cooper A.B., Doores K.J., Aoki-Ota M., Le K., Schief W.R., Wyatt R.T., Burton D.R., Nemazee D. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J. Immunol. 2013, 191:3179-3185.
20. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
21. Pejawar-Gaddy S., Kovacs J.M., Barouch D.H., Chen B., Irvine D.J. Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination. Bioconjug. Chem. 2014, 25:1470-1478.
22. Pejchal R., Walker L.M., Stanfield R.L., Phogat S.K., Koff W.C., Poignard P., Burton D.R., Wilson I.A. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. USA 2010, 107:11483-11488.
23. Plzakova L., Kubelkova K., Krocova Z., Zarybnicka L., Sinkorova Z., Macela A. B cell subsets are activated and produce cytokines during early phases of Francisella tularensis LVS infection. Microb. Pathog. 2014, 75:49-58.
24. Posner M.R., Cavacini L.A., Emes C.L., Power J., Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune Defic. Syndr. 1993, 6:7-14.
25. Ringe R.P., Yasmeen A., Ozorowski G., Go E.P., Pritchard L.K., Guttman M., Ketas T.A., Cottrell C.A., Wilson I.A., Sanders R.W., et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J. Virol. 2015, 89:12189-12210.
26. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., Lowy D.R., Wacholder S., Schiffman M., Rodriguez A.C., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev. Res. (Phila.) 2013, 6:1242-1250. CVT Group.
27. Sanders R.W., Derking R., Cupo A., Julien J.P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Peña A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
28. Sanders R.W., van Gils M.J., Derking R., Sok D., Ketas T.J., Burger J.A., Ozorowski G., Cupo A., Simonich C., Goo L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015, 349:aac4223.
29. Schiller J., Chackerian B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 2014, 10:e1004254.
30. Schiller J.T., Lowy D.R. Raising expectations for subunit vaccine. J. Infect. Dis. 2015, 211:1373-1375.
31. Sharma S.K., de Val N., Bale S., Guenaga J., Tran K., Feng Y., Dubrovskaya V., Ward A.B., Wyatt R.T. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 2015, 11:539-550.
32. Sok D., van Gils M.J., Pauthner M., Julien J.P., Saye-Francisco K.L., Hsueh J., Briney B., Lee J.H., Le K.M., Lee P.S., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 2014, 111:17624-17629.
33. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004, 12:193-204.
34. Tran E.E., Borgnia M.J., Kuybeda O., Schauder D.M., Bartesaghi A., Frank G.A., Sapiro G., Milne J.L., Subramaniam S. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012, 8:e1002797.
35. Tran K., Poulsen C., Guenaga J., de Val N., Wilson R., Sundling C., Li Y., Stanfield R.L., Wilson I.A., Ward A.B., et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. USA 2014, 111:E738-E747.
36. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70:1100-1108.
37. Victora G.D., Nussenzweig M.C. Germinal centers. Annu. Rev. Immunol. 2012, 30:429-457.
38. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602. NISC Comparative Sequencing Program.